Cargando…

Disease Burden of Glaucoma in China: Findings from the Global Burden of Disease 2019 Study

PURPOSE: To provide evidence for future strategies in preventing glaucomatous blindness by investigating the disease burden in terms of age, year, and gender from 1990 to 2019 in China. METHODS: The prevalence and disability-adjusted life years (DALYs) of blindness and vision loss due to glaucoma in...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Yi, Chen, Aiming, Zou, Minjie, Liu, Zhenzhen, Young, Charlotte Aimee, Zheng, Danying, Jin, Guangming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9266675/
https://www.ncbi.nlm.nih.gov/pubmed/35815296
http://dx.doi.org/10.2147/CLEP.S357188
_version_ 1784743526369591296
author Sun, Yi
Chen, Aiming
Zou, Minjie
Liu, Zhenzhen
Young, Charlotte Aimee
Zheng, Danying
Jin, Guangming
author_facet Sun, Yi
Chen, Aiming
Zou, Minjie
Liu, Zhenzhen
Young, Charlotte Aimee
Zheng, Danying
Jin, Guangming
author_sort Sun, Yi
collection PubMed
description PURPOSE: To provide evidence for future strategies in preventing glaucomatous blindness by investigating the disease burden in terms of age, year, and gender from 1990 to 2019 in China. METHODS: The prevalence and disability-adjusted life years (DALYs) of blindness and vision loss due to glaucoma in China were extracted from the Global Burden of Disease (GBD) 2019 study. Age-standardized data is presented in comparison to China’s neighboring countries. RESULTS: From 1990 to 2019, the prevalent cases and DALYs number with glaucomatous blindness and vision loss increased by 129.53% and 67.29%, respectively. Overall, higher age-standardized prevalence and DALYs rate were detected in males than in females between 1990 and 2019, and people aged 60 to 89 years suffered from a higher DALY number than other age groups in 2019. Among the neighboring countries, China ranked from fourth in 1990 (88.52, 95% uncertainty interval [UI]: 74.62 to 103.24, per 100,000 population) to third in 2019 (71.14, 95% UI: 59.34 to 84.42, per 100,000 population) in age-standardized prevalence while from fourth in 1990 (10.13, 95% UI: 6.68 to 14.46, per 100,000 population) to sixth in 2019 (5.98, 95% UI: 4.14 to 8.42, per 100,000 population) in age-standardized DALYs. Compared with other GBD regions, the largest decrease in age-standardized DALY rate due to glaucoma was found in China (−40.87%, 95% UI: −43.97% to −37.82%). A higher percentage decrease in age-standardized prevalence was also found in China (−19.66%, 95% UI: −22.44% to −17.09%). CONCLUSION: Substantial increases in the prevalence of visual impairment and DALYs number of glaucoma were observed from 1990 to 2019. Efforts targeting glaucoma prevention and treatment in China are urgently required, especially for the elderly population and men.
format Online
Article
Text
id pubmed-9266675
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-92666752022-07-09 Disease Burden of Glaucoma in China: Findings from the Global Burden of Disease 2019 Study Sun, Yi Chen, Aiming Zou, Minjie Liu, Zhenzhen Young, Charlotte Aimee Zheng, Danying Jin, Guangming Clin Epidemiol Original Research PURPOSE: To provide evidence for future strategies in preventing glaucomatous blindness by investigating the disease burden in terms of age, year, and gender from 1990 to 2019 in China. METHODS: The prevalence and disability-adjusted life years (DALYs) of blindness and vision loss due to glaucoma in China were extracted from the Global Burden of Disease (GBD) 2019 study. Age-standardized data is presented in comparison to China’s neighboring countries. RESULTS: From 1990 to 2019, the prevalent cases and DALYs number with glaucomatous blindness and vision loss increased by 129.53% and 67.29%, respectively. Overall, higher age-standardized prevalence and DALYs rate were detected in males than in females between 1990 and 2019, and people aged 60 to 89 years suffered from a higher DALY number than other age groups in 2019. Among the neighboring countries, China ranked from fourth in 1990 (88.52, 95% uncertainty interval [UI]: 74.62 to 103.24, per 100,000 population) to third in 2019 (71.14, 95% UI: 59.34 to 84.42, per 100,000 population) in age-standardized prevalence while from fourth in 1990 (10.13, 95% UI: 6.68 to 14.46, per 100,000 population) to sixth in 2019 (5.98, 95% UI: 4.14 to 8.42, per 100,000 population) in age-standardized DALYs. Compared with other GBD regions, the largest decrease in age-standardized DALY rate due to glaucoma was found in China (−40.87%, 95% UI: −43.97% to −37.82%). A higher percentage decrease in age-standardized prevalence was also found in China (−19.66%, 95% UI: −22.44% to −17.09%). CONCLUSION: Substantial increases in the prevalence of visual impairment and DALYs number of glaucoma were observed from 1990 to 2019. Efforts targeting glaucoma prevention and treatment in China are urgently required, especially for the elderly population and men. Dove 2022-07-04 /pmc/articles/PMC9266675/ /pubmed/35815296 http://dx.doi.org/10.2147/CLEP.S357188 Text en © 2022 Sun et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Sun, Yi
Chen, Aiming
Zou, Minjie
Liu, Zhenzhen
Young, Charlotte Aimee
Zheng, Danying
Jin, Guangming
Disease Burden of Glaucoma in China: Findings from the Global Burden of Disease 2019 Study
title Disease Burden of Glaucoma in China: Findings from the Global Burden of Disease 2019 Study
title_full Disease Burden of Glaucoma in China: Findings from the Global Burden of Disease 2019 Study
title_fullStr Disease Burden of Glaucoma in China: Findings from the Global Burden of Disease 2019 Study
title_full_unstemmed Disease Burden of Glaucoma in China: Findings from the Global Burden of Disease 2019 Study
title_short Disease Burden of Glaucoma in China: Findings from the Global Burden of Disease 2019 Study
title_sort disease burden of glaucoma in china: findings from the global burden of disease 2019 study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9266675/
https://www.ncbi.nlm.nih.gov/pubmed/35815296
http://dx.doi.org/10.2147/CLEP.S357188
work_keys_str_mv AT sunyi diseaseburdenofglaucomainchinafindingsfromtheglobalburdenofdisease2019study
AT chenaiming diseaseburdenofglaucomainchinafindingsfromtheglobalburdenofdisease2019study
AT zouminjie diseaseburdenofglaucomainchinafindingsfromtheglobalburdenofdisease2019study
AT liuzhenzhen diseaseburdenofglaucomainchinafindingsfromtheglobalburdenofdisease2019study
AT youngcharlotteaimee diseaseburdenofglaucomainchinafindingsfromtheglobalburdenofdisease2019study
AT zhengdanying diseaseburdenofglaucomainchinafindingsfromtheglobalburdenofdisease2019study
AT jinguangming diseaseburdenofglaucomainchinafindingsfromtheglobalburdenofdisease2019study